ILB-3132（E12LA6B603)
Version 1.c1f27833 · 2026-09-13
| CAS No. | Not available |
| Chemical Name | ILB-3132（E12LA6B603) |
| Synonyms | ILB3132， ILB 3132 |
| SMILES | CCCCCCCCCCC(COC(=O)CCCCC)OC(=O)CCCCCN(CCCO)CCCCCC(=O)OC(CCCCCCCCCC)COC(=O)CCCCC |
| Formula | C51H97NO9 |
| M.Wt | 868.335 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | In vivo CD19-CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus-Qian Wang etl. N Engl J Med. 2025 Sep 17. doi: 10.1056/NEJMc2509522 WO2024198497A1 |
E12LA6B603（ILB3132，ILB-3132） is a novel ionizable amino lipid disclosed in patent WO2024198497A1, developed by MagicRNA, representing a highly efficient component for lipid nanoparticle (LNP) delivery systems.When formulated into LNPs, E12LA6B603 LNP achieves a remarkable 98.26% encapsulation efficiency for mRNA. It mediates superior in vitro transfection in dendritic cells (1.8E+05 intensity) and demonstrates best-in-class in vivo protein expression after intramuscular injection (2.2E+09 intensity). Most notably, in a B16-OVA melanoma model, therapeutic OVA-mRNA vaccines delivered by E12LA6B603 LNPs induced 100% complete tumor regression, highlighting its superior efficacy over benchmarks like DLin-MC3 and SM-102. Its biodegradable ester linkages and balanced structure make it a promising, potent candidate for next-generation mRNA vaccines and therapeutics.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →